NasdaqGS:REPL

Stock Analysis Report

Executive Summary

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer.

Risk Analysis

Earnings are forecast to decline by an average of -29.2% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months



Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Replimune Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: REPL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.3%

REPL

1.2%

US Biotechs

1.2%

US Market


1 Year Return

78.6%

REPL

12.4%

US Biotechs

24.2%

US Market

Return vs Industry: REPL exceeded the US Biotechs industry which returned 10.9% over the past year.

Return vs Market: REPL exceeded the US Market which returned 24.7% over the past year.


Shareholder returns

REPLIndustryMarket
7 Day5.3%1.2%1.2%
30 Day27.9%0.2%3.5%
90 Day28.2%17.5%11.7%
1 Year78.6%78.6%13.4%12.4%26.9%24.2%
3 Yearn/a30.1%25.8%53.0%43.2%
5 Yearn/a2.6%-2.3%75.3%56.0%

Price Volatility Vs. Market

How volatile is Replimune Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Replimune Group undervalued compared to its fair value and its price relative to the market?

4.98x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: REPL ($18.93) is trading above our estimate of fair value ($15.5)

Significantly Below Fair Value: REPL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: REPL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: REPL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate REPL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: REPL is overvalued based on its PB Ratio (4.7x) compared to the US Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Replimune Group forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-32.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: REPL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: REPL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: REPL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if REPL's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if REPL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if REPL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Replimune Group performed over the past 5 years?

-24.9%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: REPL is currently unprofitable.

Growing Profit Margin: REPL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if REPL's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare REPL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: REPL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: REPL has a negative Return on Equity (-28.99%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Replimune Group's financial position?


Financial Position Analysis

Short Term Liabilities: REPL's short term assets ($118.0M) exceed its short term liabilities ($12.0M).

Long Term Liabilities: REPL's short term assets ($118.0M) exceed its long term liabilities ($18.8M).


Debt to Equity History and Analysis

Debt Level: REPL's debt to equity ratio (8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if REPL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: REPL has a low level of unsold assets or inventory.

Debt Coverage by Assets: REPL's debt is covered by short term assets (assets are 12.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: REPL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: REPL has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of -61.8% each year.


Next Steps

Dividend

What is Replimune Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate REPL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate REPL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if REPL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if REPL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of REPL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Replimune Group's salary, the management and board of directors tenure and is there insider trading?

4.2yrs

Average management tenure


CEO

Philip Astley-Sparke (48yo)

0yrs

Tenure

US$1,812,591

Compensation

Mr. Philip Astley-Sparke, FSA, is a Co-founder of Replimune Group, Inc. and serves as its Executive Chairman since 2015. Mr. Astley-Sparke is Chief Executive Officer, Secretary and Treasurer at Replimune G ...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD2.27M) is about average for companies of similar size in the US market ($USD2.53M).

Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.2yrs

Average Tenure

53.5yo

Average Age

Experienced Management: REPL's management team is considered experienced (4.2 years average tenure).


Board Age and Tenure

4.3yrs

Average Tenure

54yo

Average Age

Experienced Board: REPL's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$14,971,00020 Nov 19
Atlas Venture L.P.
EntityCompany
Shares1,100,000
Max PriceUS$13.61
BuyUS$2,994,20020 Nov 19
Omega Fund Management, LLC
EntityCompany
Shares220,000
Max PriceUS$13.61

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 219.2%.


Management Team

  • Rob Coffin (54yo)

    Founder

    • Tenure: 5yrs
    • Compensation: US$2.27m
  • Philip Astley-Sparke (48yo)

    Chairman

    • Compensation: US$1.81m
  • Colin Love (61yo)

    Chief Operating Officer

    • Tenure: 4.3yrs
    • Compensation: US$1.30m
  • Jean Franchi (53yo)

    Chief Financial Officer

    • Tenure: 0.08yrs
  • Pamela Esposito (44yo)

    Chief Business Officer

    • Tenure: 4.2yrs
    • Compensation: US$601.20k
  • Stephen Gorgol (60yo)

    Chief Accounting Officer


    Board Members

    • Joe Slattery (54yo)

      Lead Independent Director

      • Tenure: 0.8yrs
      • Compensation: US$158.83k
    • Jason Rhodes (49yo)

      Independent Director

      • Tenure: 4.3yrs
      • Compensation: US$151.26k
    • Rob Coffin (54yo)

      Founder

      • Tenure: 5yrs
      • Compensation: US$2.27m
    • Philip Astley-Sparke (48yo)

      Chairman

      • Compensation: US$1.81m
    • Sander Slootweg (51yo)

      Independent Director

      • Tenure: 5yrs
      • Compensation: US$144.48k
    • Otello Stampacchia (45yo)

      Independent Director

      • Tenure: 4.7yrs
      • Compensation: US$117.59k
    • Hy Levitsky (61yo)

      Independent Non-Executive Director

      • Tenure: 1.7yrs
      • Compensation: US$262.53k
    • Kapil Dhingra (60yo)

      Independent Director

      • Tenure: 2.5yrs
      • Compensation: US$156.16k
    • Dieter Weinand (59yo)

      Independent Director

      • Tenure: 1.6yrs
      • Compensation: US$262.65k

    Company Information

    Replimune Group, Inc.'s company bio, employee growth, exchange listings and data sources


    Key Information

    • Name: Replimune Group, Inc.
    • Ticker: REPL
    • Exchange: NasdaqGS
    • Founded: 2015
    • Industry: Biotechnology
    • Sector: Pharmaceuticals & Biotech
    • Market Cap: US$670.072m
    • Shares outstanding: 35.40m
    • Website: https://www.replimune.com

    Number of Employees


    Location

    • Replimune Group, Inc.
    • 18 Commerce Way
    • Woburn
    • Massachusetts
    • 1801
    • United States

    Listings

    TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
    REPLNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2018
    7R8DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2018

    Biography

    Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. It is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. 


    Company Analysis and Financial Data Status

    All financial data provided by Standard & Poor's Capital IQ.
    DataLast Updated (UTC time)
    Company Analysis2020/01/21 01:44
    End of Day Share Price2020/01/17 00:00
    Earnings2019/09/30
    Annual Earnings2019/03/31


    Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.